Flaviane Nunes Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Flaviane Nunes Silva has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Barbara Burtness
Yale School of Medicine and Yale Cancer Center New Haven Connecticut USA
18 shared publications - Erica A. Golemis
Program in Cancer Signaling and Microenvironment, Fox Chase Cancer Center, Philadelphia, USA
18 shared publications - Fiona M. Goeckel
Chestnut Hill College, Philadelphia, Pennsylvania
18 shared publications - Hossein Borghaei
Fox Chase Cancer Center, Philadelphia, PA
18 shared publications - Jong Woo Lee
Yale Cancer Center 3 Section of Medical Oncology, Department of Internal Medicine Yale University School of Medicine, New Haven, Connecticut
18 shared publications - Tetyana Bagnyukova
Fox Chase Cancer Center 1 Cancer Signaling and Microenvironment Program Philadelphia, Pennsylvania
18 shared publications
Latest Publications
- Open Access
- 13 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma
Signaling consequences in Fadu parental, AfaR, or ErlR cells of treatment with VIC-1911 alone or in combination with erlotinib or afatinib
- 13 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma
Signaling consequences in Fadu parental, AfaR, or ErlR cells of treatment with VIC-1911 alone or in combination with erlotinib or afatinib
- Open Access
- 13 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma
Cell cycle profiles of Fadu parental and AfaR cell models after 1, 3, or 5 days treatment with VIC-1911
- 13 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma
Cell cycle profiles of Fadu parental and AfaR cell models after 1, 3, or 5 days treatment with VIC-1911
- Open Access
- 13 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma
Efficacy of a VIC-1911 combination with adavosertib in parental, AfaR, and ErlR HNSCC cell models. A, Loewe synergy plot showing synergistic interaction between VIC-1911 and adavosertib in parental, ErlR, and AfaR cell models treated for 72 hours, n = 3. B, Percentage of cells in G2–M (4N DNA content) for parental, ErlR, and AfaR cell models treated with DMSO, VIC-1911 (0.25 μmol/L), adavosertib (0.5 μmol/L), or combination for 24 hours. C and D, Quantification of dead FaDu (C) and Cal27 (D) parental, ErlR, and AfaR cell models treated with vehicle, adavosertib (0.5 μmol/L), VIC-1911 (0.25 μmol/L), or combination for 72 hours (n = 3). E and F, Representative Western blot images showing PARP and cleaved PARP (cPARP) for parental, ErlR, and AfaR cell models treated with DMSO, VIC-1911 (0.25 μmol/L), adavosertib (0.5 μmol/L), or combination for 24 hours, n = 3. G and H, Representative images (G) and quantitation of viability based on CellTiter-Glo (H) for spheroids of indicated cell models. I and J, Representative images (I) and quantification (J) of clonogenic assays for cells treated with the drug concentration indicated in I for 11 days. Bar graphs display data normalized to DMSO values of each cell line. P values are based on one-way ANOVA followed by the Tukey multiple comparison test. ns, not significant; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. Data are shown as mean ± SEM of three biological replicates.
- 13 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma
Efficacy of a VIC-1911 combination with adavosertib in parental, AfaR, and ErlR HNSCC cell models. A, Loewe synergy plot showing synergistic interaction between VIC-1911 and adavosertib in parental, ErlR, and AfaR cell models treated for 72 hours, n = 3. B, Percentage of cells in G2–M (4N DNA content) for parental, ErlR, and AfaR cell models treated with DMSO, VIC-1911 (0.25 μmol/L), adavosertib (0.5 μmol/L), or combination for 24 hours. C and D, Quantification of dead FaDu (C) and Cal27 (D) parental, ErlR, and AfaR cell models treated with vehicle, adavosertib (0.5 μmol/L), VIC-1911 (0.25 μmol/L), or combination for 72 hours (n = 3). E and F, Representative Western blot images showing PARP and cleaved PARP (cPARP) for parental, ErlR, and AfaR cell models treated with DMSO, VIC-1911 (0.25 μmol/L), adavosertib (0.5 μmol/L), or combination for 24 hours, n = 3. G and H, Representative images (G) and quantitation of viability based on CellTiter-Glo (H) for spheroids of indicated cell models. I and J, Representative images (I) and quantification (J) of clonogenic assays for cells treated with the drug concentration indicated in I for 11 days. Bar graphs display data normalized to DMSO values of each cell line. P values are based on one-way ANOVA followed by the Tukey multiple comparison test. ns, not significant; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. Data are shown as mean ± SEM of three biological replicates.
- Open Access
- 13 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma
Combined AURKA and WEE inhibition reduces Ki-67, and elevates caspase-3, AURKA and TPX2 expression in xenograft tumors.
- 13 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma
Combined AURKA and WEE inhibition reduces Ki-67, and elevates caspase-3, AURKA and TPX2 expression in xenograft tumors.
- Open Access
- 13 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma
Response of parental, AfaR, and ErlR models to AURKAi combinations with erlotinib or afatinib. A, Loewe synergy plot showing synergistic interaction between VIC-1911 and afatinib or erlotinib in FaDu and Cal27 parental, ErlR, and AfaR cell lines treated for 72 hours, n = 3. B, Quantification of dead cells from the models indicated treated for 72 hours with drugs indicated. FaDu and derived models were treated with vehicle, VIC-1911 (0.6 μmol/L), afatinib (0.2 μmol/L), erlotinib (1 μmol/L), or combination. Cal27 and derived models were treated with vehicle, VIC-1911 (0.6 μmol/L), afatinib (0.8 μmol/L), erlotinib (2 μmol/L), or combination for 24 hours. C and D, Clonogenic survival assay primary data (C) and corresponding (D) quantification. Cells were treated with the drug concentration indicated in C for 11 days. E, Quantification of annexin-positive cells for Fadu parental and Fadu AfaR treated for 3 days (left) and 5 days (right) with VIC-1911 (600 nmol/L). P values are based on one-way ANOVA followed by the Tukey multiple comparison test. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. Data are shown as mean ± SEM of three biological replicates.
- 13 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma
Response of parental, AfaR, and ErlR models to AURKAi combinations with erlotinib or afatinib. A, Loewe synergy plot showing synergistic interaction between VIC-1911 and afatinib or erlotinib in FaDu and Cal27 parental, ErlR, and AfaR cell lines treated for 72 hours, n = 3. B, Quantification of dead cells from the models indicated treated for 72 hours with drugs indicated. FaDu and derived models were treated with vehicle, VIC-1911 (0.6 μmol/L), afatinib (0.2 μmol/L), erlotinib (1 μmol/L), or combination. Cal27 and derived models were treated with vehicle, VIC-1911 (0.6 μmol/L), afatinib (0.8 μmol/L), erlotinib (2 μmol/L), or combination for 24 hours. C and D, Clonogenic survival assay primary data (C) and corresponding (D) quantification. Cells were treated with the drug concentration indicated in C for 11 days. E, Quantification of annexin-positive cells for Fadu parental and Fadu AfaR treated for 3 days (left) and 5 days (right) with VIC-1911 (600 nmol/L). P values are based on one-way ANOVA followed by the Tukey multiple comparison test. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. Data are shown as mean ± SEM of three biological replicates.
- Open Access
- 13 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma
Characterization of baselines and biological response to AURKA inhibition in parental, AfaR, and ErlR HNSCC cell lines.
- 13 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma
Characterization of baselines and biological response to AURKA inhibition in parental, AfaR, and ErlR HNSCC cell lines.
- Open Access
- 13 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma
Signaling changes induced by treatment with VIC-1911 and adavosertib in parental, AfaR, and ErlR HNSCC models. A–E, Representative Western blots and quantification for phospho-CDK1 (Y15) and total-CDK1 (A), γH2AX (S139; B), TPX2 (C), total AURKA (D), and NEDD9 (E) in FaDu parental, ErlR, and AfaR cell models treated with DMSO, VIC-1911 (0.25 μmol/L), adavosertib (0.5 μmol/L), or combination for 24 hours. A and B share the same loading control, as they were derived from the same gel. Bar graphs display data normalized to the DMSO of each cell line. P values are based on one-way ANOVA followed by the Tukey multiple comparison test. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. Data are shown as mean ± SEM of three biological replicates.
- 13 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma
Signaling changes induced by treatment with VIC-1911 and adavosertib in parental, AfaR, and ErlR HNSCC models. A–E, Representative Western blots and quantification for phospho-CDK1 (Y15) and total-CDK1 (A), γH2AX (S139; B), TPX2 (C), total AURKA (D), and NEDD9 (E) in FaDu parental, ErlR, and AfaR cell models treated with DMSO, VIC-1911 (0.25 μmol/L), adavosertib (0.5 μmol/L), or combination for 24 hours. A and B share the same loading control, as they were derived from the same gel. Bar graphs display data normalized to the DMSO of each cell line. P values are based on one-way ANOVA followed by the Tukey multiple comparison test. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. Data are shown as mean ± SEM of three biological replicates.
- Open Access
- 13 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 6 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma
In vivo response of FaDu parental and FaduAfaR xenografts to VIC-1911 + adavosertib drug combination. A, Mice harboring either FaDu parental or FaDuAfaR xenograft tumors were daily treated with vehicle (n = 8 for parental, n = 5 for AfaR) or VIC-1911 60 mg/kg (n = 8 for parental, n = 5 for AfaR) for 12 days to compare response to monotherapy. B and C, Mice harboring FaDu parental (B) or FaduAfaR (C) xenografts were daily treated with vehicle (n = 7), adavosertib 120 mg/kg (n = 7), VIC-1911 30 mg/kg (n = 8), or combination (n = 8) for 21 days. P values are based on two-way ANOVA followed by the Tukey multiple comparison test. D and E, Representative IHC staining images (D) and quantification (E) of Ki-67 and cleaved caspase 3 in FaDu parental or FaDuAfaR xenograft tumors treated with the indicated drugs. Mice harboring FaDu parental or FaDuAfaR xenografts were daily treated with vehicle (n = 7), adavosertib 120 mg/kg (n = 7), VIC-1911 30 mg/kg (n = 8), or combination (n = 8) for 21 days. Scale bars, 300 μm. Violin plots display median (-) and quartiles (…). P values are based on two-way ANOVA followed by the Tukey multiple comparison test. Only significant comparisons are displayed in the violin plots. P = 0.0332; **, P = 0.0021; ***, P = 0.0002; ****, P ≤ 0.0001.
- 13 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma
In vivo response of FaDu parental and FaduAfaR xenografts to VIC-1911 + adavosertib drug combination. A, Mice harboring either FaDu parental or FaDuAfaR xenograft tumors were daily treated with vehicle (n = 8 for parental, n = 5 for AfaR) or VIC-1911 60 mg/kg (n = 8 for parental, n = 5 for AfaR) for 12 days to compare response to monotherapy. B and C, Mice harboring FaDu parental (B) or FaduAfaR (C) xenografts were daily treated with vehicle (n = 7), adavosertib 120 mg/kg (n = 7), VIC-1911 30 mg/kg (n = 8), or combination (n = 8) for 21 days. P values are based on two-way ANOVA followed by the Tukey multiple comparison test. D and E, Representative IHC staining images (D) and quantification (E) of Ki-67 and cleaved caspase 3 in FaDu parental or FaDuAfaR xenograft tumors treated with the indicated drugs. Mice harboring FaDu parental or FaDuAfaR xenografts were daily treated with vehicle (n = 7), adavosertib 120 mg/kg (n = 7), VIC-1911 30 mg/kg (n = 8), or combination (n = 8) for 21 days. Scale bars, 300 μm. Violin plots display median (-) and quartiles (…). P values are based on two-way ANOVA followed by the Tukey multiple comparison test. Only significant comparisons are displayed in the violin plots. P = 0.0332; **, P = 0.0021; ***, P = 0.0002; ****, P ≤ 0.0001.
- Open Access
- 13 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma
Characterization of erlotinib-resistant (ErlR) and afatinib-resistant (AfaR) HNSCC cell models.
- 13 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma
Characterization of erlotinib-resistant (ErlR) and afatinib-resistant (AfaR) HNSCC cell models.
- Open Access
- 13 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma
More than 600,000 cases of head and neck squamous cell carcinoma (HNSCC) are diagnosed globally each year. Many HNSCCs overexpress the ERBB family member epidermal growth factor receptor (EGFR), and EGFR inhibitors (EGFRi) and pan-ERBB inhibitors (ERBBi) are clinically active in the treatment of locally advanced, metastatic, or recurrent HNSCC. However, resistance to these inhibitors typically develops, often associated with epithelial–mesenchymal transition (EMT). Aurora kinase A (AURKA), a mitotic regulator with expanded signaling functions in tumors, has been reported to reverse EGFR resistance in EGFR-mutated lung cancer. To identify strategies to overcome resistance in HNSCC, we developed HNSCC cell models that were treatment-naïve parental or selected for resistance to the EGFRi erlotinib or the ERBBi afatinib. The resistant HNSCC models had typically undergone partial EMT, consistent with clinical resistance, associated with upregulation of the AURKA partner protein NEDD9. Synergy of the AURKA inhibitor VIC-1911 with erlotinib or afatinib in parental models was reduced in resistant models in short-term growth assays. In longer-term clonogenic assays and in vivo, cells selected for EGFRi/ERBBi resistance showed heightened sensitivity to VIC-1911, contributing to reduced synergy. Based on increased AURKA dependence, we compared the combination of VIC-1911 with adavosertib, an inhibitor of the cell-cycle checkpoint regulator WEE1, in parental and resistant models. These showed a combination effect both in vitro and in vivo that was retained in ERBBi-resistant xenografts, suggesting the potential value of combined AURKA and WEE1 inhibitor use in patients with ERBBi-resistant HNSCC. Significance:Treatment resistance is a major source of mortality for HNSCC. This study investigates strategies to overcome resistance to inhibitors of the ERBB family, which are commonly used for the treatment of advanced HNSCC. The results suggest the value of the use of combined AURKA and WEE inhibition in the resistance setting.
- 13 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma
More than 600,000 cases of head and neck squamous cell carcinoma (HNSCC) are diagnosed globally each year. Many HNSCCs overexpress the ERBB family member epidermal growth factor receptor (EGFR), and EGFR inhibitors (EGFRi) and pan-ERBB inhibitors (ERBBi) are clinically active in the treatment of locally advanced, metastatic, or recurrent HNSCC. However, resistance to these inhibitors typically develops, often associated with epithelial–mesenchymal transition (EMT). Aurora kinase A (AURKA), a mitotic regulator with expanded signaling functions in tumors, has been reported to reverse EGFR resistance in EGFR-mutated lung cancer. To identify strategies to overcome resistance in HNSCC, we developed HNSCC cell models that were treatment-naïve parental or selected for resistance to the EGFRi erlotinib or the ERBBi afatinib. The resistant HNSCC models had typically undergone partial EMT, consistent with clinical resistance, associated with upregulation of the AURKA partner protein NEDD9. Synergy of the AURKA inhibitor VIC-1911 with erlotinib or afatinib in parental models was reduced in resistant models in short-term growth assays. In longer-term clonogenic assays and in vivo, cells selected for EGFRi/ERBBi resistance showed heightened sensitivity to VIC-1911, contributing to reduced synergy. Based on increased AURKA dependence, we compared the combination of VIC-1911 with adavosertib, an inhibitor of the cell-cycle checkpoint regulator WEE1, in parental and resistant models. These showed a combination effect both in vitro and in vivo that was retained in ERBBi-resistant xenografts, suggesting the potential value of combined AURKA and WEE1 inhibitor use in patients with ERBBi-resistant HNSCC. Significance:Treatment resistance is a major source of mortality for HNSCC. This study investigates strategies to overcome resistance to inhibitors of the ERBB family, which are commonly used for the treatment of advanced HNSCC. The results suggest the value of the use of combined AURKA and WEE inhibition in the resistance setting.